Leptin-mediated regulation of ICAM-1 is Rho|[sol]|ROCK dependent and enhances gastric cancer cell migration

Z Dong,ssui fu,xiangbin xu,yan yang,liying du,wei li,S Kan,zhanqing li,xiaochun zhang,L Wang,jin li,hui liu,xueping qu,C Wang

DOI: https://doi.org/10.1038/bjc.2014.70

IF: 9.075

2014-01-01

British Journal of Cancer

Abstract:Gastric cancer (GC) ranks as the second leading cause of cancer-related death in the world (Parkin et al, 2005). The high aggressiveness and rapid metastasis of GC contribute to its high mortality rate (Wang and Chen, 2011). The metastasis involves multiple factors, such as obesity, an important risk factor in GC (Calle et al, 2003; Howard et al, 2010). Adipocytes provide fatty acids for rapid tumour growth, and the dysfunction of lipid metabolism can lead to the pathogenesis of human GC (Song et al, 2012). Leptin is an adipokine of the obesity (ob) gene, and has been known to have roles in the homeostasis of body weight by regulating food intake and energy metabolism (Chan et al, 2006). Recent studies have revealed that leptin is implicated in the tumorigenesis of cancer, such as ovarian cancer, endometrial cancer, GC, and so on (Zhao et al, 2007; Wu et al, 2012; Xu et al, 2013). Leptin exerts its function through leptin receptor, and the use of leptin receptor antagonists has been recognised as a potential therapeutic approach for cancer (Otvos et al, 2011). Our previous study indicates that leptin enhances GC cell invasion by upregulating the expression of membrane type 1-matrix metalloproteinase (MT1-MMP) (Dong et al, 2013). Converging studies reveal that leptin expression is elevated in GC patients, and is also significantly correlated with GC metastasis (Shida et al, 2005; Ishikawa et al, 2006; Zhao et al, 2007). However, the exact effect of leptin on GC metastasis and its underlying mechanism remain poorly understood. Recent findings of upregulation of intercellular adhesion molecule-1 (ICAM-1, also known as CD54) by leptin in allergic inflammation may shed light on how leptin modulates cell migration (Wong et al, 2007). This suggests a link between leptin and ICAM-1. ICAM-1 is a transmembrane glycoprotein of the immunoglobulin superfamily. It binds to two major ligands, lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18) and macrophage-1 antigen (Mac-1, CD11b/CD18). LFA-1 and Mac-1 expressed on NK cell and macrophages share a common β chain (Diamond et al, 1990; Zimmerman and Blanco, 2008). ICAM-1 has an essential role in cell–cell and cell–extracellular matrix interaction. Binding to LFA-1 and Mac-1, ICAM-1 can facilitate the metastasis of cancer cells by escaping the recognition and attack of immunocytes (Makrilia et al, 2009). Previous studies show that ICAM-1 is associated with more aggressive lesions in prostate cancer (Chen et al, 2012), lung cancer (Grothey et al, 1998), and GC (Maruo et al, 2002). Laboratory models have demonstrated that the upregulation of ICAM-1 can promote tumour cell invasion and metastasis. In addition, overexpressed ICAM-1 may be released from the local cancer cell nests and enter the serum as sICAM-1 (Essick et al, 2008). Elevated serum ICAM-1 level is correlated significantly with serum CA19-9 and CEA in GC (Polychronidis et al, 2003); consistently, suppression of ICAM-1 expression is related to attenuated tumour progression and metastasis (Kaliora et al, 2008; Chen et al, 2012; Yu et al, 2012). Interestingly, both leptin and ICAM-1 are increased after Helicobacter pylori infection (Fan et al, 1995; Azuma et al, 2001). To our knowledge, there is no published data about the effect of leptin on ICAM-1 and its role in GC metastasis. The expression of ICAM-1 may be regulated by a variety of signalling pathways, such as Rho (the small G protein Ras homologue gene family) and its immediate downstream effector Rho-associated coiled-coil-forming protein kinase (ROCK) (Jung et al, 2012). ROCK is ubiquitously expressed serine–threonine protein kinases that are involved in diverse cellular functions, including actin cytoskeleton organisation, cell adhesion, and motility (Burridge and Wennerberg, 2004). Hyperactivation of the Rho/ROCK pathway is known to be linked with more aggressive tumour properties such as metastasis (Sahai and Marshall, 2002). Rho/ROCK may be regulated by some factors in tumours. For example, lysophosphatidic acid triggers focal adhesion assembly through Rho/ROCK pathway in human ovarian cancer cells (Sawada et al, 2002). A previous study reveals that leptin may induce Rho/ROCK pathway (Schram et al, 2011). On the basis of these reports, we hypothesise that Rho/ROCK pathway may be involved in the leptin-mediated expression of ICAM-1. This study has demonstrated that leptin promotes the migration of GC cells by upregulating ICAM-1 expression via the involvement of Rho/ROCK pathway. Targeting ICAM-1 and its regulation pathway might provide preliminary experimental clues for the development of therapies against the metastasis of GC. To test whether leptin-mediated ICAM-1 upregulation was involved in GC cell migration, we first transduced GC cells to overexpress ICAM-1 (pcDNA3.1-ICAM-1). The transfection efficacy was analysed by WB (Figure 4A). Our findings showed that overexpressed ICAM-1 could promote GC cell migration (Figure 4B). Moreover, we performed knockdown of ICAM-1 by siRNA. The knockdown efficiency was evaluated by WB (Figure 4C). As shown in Figure 4D, leptin-induced migration of GC cells was significantly reduced by transient transfection of ICAM-1-siRNA (AGS: 53.9%±3.6%, P=0.020; MKN-45: 42.79%±3.78%, P=0.005). The NC group was transfected with control siRNA. To further explore whether leptin regulated the expression of ICAM-1 through the Rho/ROCK pathway, cells were pretreated with the specific pharmacological inhibitor C3 transferase (Rho inhibitor; Cytoskeleton) at 0.25 μg ml−1 or Y-27632 (ROCK inhibitor; Calbiochem, Nottingham, UK) at 3.3 μM (Schram et al, 2011), followed by leptin treatment. The expression of ICAM-1 was analysed by WB, flow cytometry, and ELISA (for sICAM-1). As shown in Figure 5C, pretreatment with either Rho (C3 transferase) or ROCK (Y-27632) inhibitor prevented the leptin-induced upregulation of ICAM-1 in AGS and MKN-45 cells, and there was no difference between C3 transferase and Y-27632. Although treatment with inhibitors alone resulted in a subtle decrease in the expression of ICAM-1 compared with control, the inhibitors alone did not influence the expression of ICAM-1. A similar trend was also observed with the cell surface ICAM-1 (Figure 5D) and sICAM-1 (Figure 5E). Metastasis, such as lymph node metastasis, is a common cause of death from GC (Wang and Chen, 2011). Leptin has been associated with an increased risk of GC and has critical roles in tumour metastasis (Zhao et al, 2007). However, little is known about the exact effect of leptin on GC cell migration and its underlying mechanism. ICAM-1 is overexpressed in several cancers and implicated in tumour migration (Maruo et al, 2002; Chen et al, 2012). In this study, leptin and ICAM-1 levels were strongly correlated with each other in human GC tissues, as well as with clinical stage and lymph node metastasis, suggesting a causal connection between leptin pathway and ICAM-1. Our results also demonstrated that leptin may enhance the migration of GC cells (AGS and MKN-45) by upregulating ICAM-1 expression in vitro. Moreover, leptin induces the activation of Rho/ROCK pathway, which contributes to the subsequent upregulation of both surface ICAM-1 and sICAM-1. Taken together, our findings indicate that leptin enhances GC migration by increasing ICAM-1 expression through Rho/ROCK pathway. Metastasis is a multi-step process during which cancer cells detach from the primary tumour, migrate, adhere, and invade into the blood or lymphatic vessels. Finally cancer cells extravasate out of the vessel and interact with the target tissue. Although multiple factors are involved in this process, adipocyte provides fatty acids for rapid tumour growth, and the dysfunction of lipid metabolism can lead to the pathogenesis of GC (Song et al, 2012). Leptin, secreted predominantly from adipocytes, may promote GC cell proliferation, suggesting an essential role of leptin in the progression of GC (Pai et al, 2005; Shida et al, 2005). This study has indicated that leptin induces the migration of GC cells (AGS and MKN-45) in a dose- and time-dependent manner, which keeps in line with previous studies that leptin induces migration of endometrial cancer and glioma cells (Yeh et al, 2009; Wu et al, 2012). Further clarifying the mechanisms responsible for leptin-induced GC metastasis is important for better understanding and control of tumour metastasis in patients with GC. Our results revealed that leptin and ICAM-1 were overexpressed in GC tissue and correlated with lymph node metastasis, which is consistent with the previous studies (Maruo et al, 2002; Zhao et al, 2007). Further analysis indicated that leptin was positively correlated with ICAM-1, suggesting a possible link between leptin and ICAM-1 in the progression of GC. This is also supported by the findings that leptin and ICAM-1 are elevated after stimulation with inflammatory cytokines, for example, in patients with H. pylori infection (Fan et al, 1995; Azuma et al, 2001). Previous studies show that ICAM-1 undergoes cleavage at its extracellular stalk domain, and release a soluble form of the protein (sICAM-1), and this process may be mediated by MT1-MMP (MMP14) (Essick et al, 2008). In this study, we found that leptin enhanced the expression of ICAM-1, as well as cell surface ICAM-1 and sICAM-1 in GC cells. Furthermore, we also observed an enhanced expression of MT1-MMP by leptin in GC cells (Dong et al, 2013). Therefore, we speculate that leptin promotes ICAM-1 expression and subsequently enhances the level of sICAM-1 via upregulating MT1-MMP. Increased ICAM-1 may promote the adhesion of cancer cells, leading to tumour growth and mediating cell–extracellular matrix interaction. When metastasis occurs, cancer cells detach from the primary lesion, penetrate through the tissue basement membrane, and invade blood vessels and lymphatic vessels. On the other hand, as the host killer cells (NK cells, LAK cells, and CTLs) and macrophages express LFA-1 and Mac-1, two major receptors of ICAM-1, partially via which they recognise and attack the tumour cells (Diamond et al, 1990), upregulated sICAM-1 may inhibit NK and macrophage activity by competitively binding to LFA-1 and Mac-1 (Koyama, 1994). Thus, it is possible that there is a balance between ICAM-1/sICAM-1 and immunocytes, which can also be explained by the fact that it takes a long time for detectable tumour to form a metastatic lesion. With the development of GC, leptin increased sICAM-1 level, breaking the balance and subsequently resulting in a failure of the host immunocytes to effectively kill the tumour cells, which may have, therefore, protected the tumour cells from elimination and facilitated tumour migration. The hypothesis is well supported by previous findings that serum leptin and sICAM-1 are elevated and positively correlated with the clinical stage and lymph node metastasis of tumour (Maruo et al, 2002; Capelle et al, 2009). Taken together, these results suggest that leptin/ICAM-1/sICAM-1 is implicated in GC metastasis and may thus provide a potential therapeutic target against GC, which needs to be further confirmed by more experiments with animal models. Sunami et al (2000) have shown that lymph node metastasis reduced after successful transfection of ICAM-1 gene into the cancer cells. Because of the enhancement of immune surveillance mechanism, tumour cells might be easily captured and destroyed by the lymphocytes. However, their cell model is different from ours, in addition, these authors did not discuss the production of sICAM-1 in their ICAM-1-overexpressing cells, though previous study from the same group revealed that the survival rate in high sICAM-1 group significantly decreased compared with that in low sICAM-1 group (Nakata et al, 2000). The present study has demonstrated the importance of leptin-induced upregulation of ICAM-1 in GC cell migration and further elucidated the underlying mechanism. It is well known that the activity of small GTPases (including RhoA) is important for the signalling derived from lipid metabolism (Bolick et al, 2005). This study has shown that leptin may activate Rho/ROCK pathway, which is consistent with the previous findings that leptin regulates myocardial matrix remodelling by activating Rho/ROCK (Schram et al, 2011). Further analysis indicates that the inhibitor of either Rho (C3 transferase) or ROCK (Y27632) attenuates leptin-induced ICAM-1 expression, illustrating that the use of ROCK inhibitors might be a potential therapeutic approach. This is also supported by the finding that Rho/ROCK pathway critically regulates the plasticity of metastatic GC (Matsuoka et al, 2011). Notably, the inhibitor treatment in this study failed to completely block the leptin-induced upregulation of ICAM-1, implying a possible contribution from other unidentified leptin-activated pathway(s). Several signalling pathways activated by leptin have been identified in GC, that is, Janus kinase/signal transducers and activators of transcription (JAK/STAT), extracellular signal-regulated kinase 1/2 (ERK1/2), and mitogen-activated protein kinase (MAPK) pathways, as well as phosphatidylinositol 3-kinase (PI3K)/AKT pathways (Pai et al, 2005; Shida et al, 2005). Previous study reveals that leptin upregulates ICAM-1 expression in eosinophils by the combined activation of MAPK and JAK pathways under allergic inflammation (Wong et al, 2007). However, their changes were not examined in this study. Although we cannot exclude the possible effect of these signalling pathways, the upregulation of ICAM-1 induced by leptin in the cells of this study might primarily depend on the RhoA/ROCK pathway. Further experiments will be conducted to test these possibilities. In addition, Rho GTPases are the binary switch between an active GTP-bound form and an inactive GDP-bound form. This process might be mediated by several molecules, such as Rho guanine nucleotide exchange factors (Rossman et al, 2005), NF-κB (Jung et al, 2012), and reactive oxygen species (Jin et al, 2004). Although these mechanisms remain an interesting research topic, they are beyond the scope of the current study. In conclusion, this study has shown that leptin enhances GC cell migration by increasing ICAM-1 expression, which is demonstrated to be largely dependent on the activation of Rho/ROCK signalling pathway. A summarised schematic diagram is shown in Figure 6. Our results may provide preliminary experimental clues for future development of novel therapies against the metastasis of GC. The authors declare no conflict of interest. The project was supported by the China National Natural Science Foundation Projects (Grant No. 81072406, 81271916, 31270971, and 81301506), Research Fund for the Doctoral Program of Higher Education of China (Grant No. 20120131110055), Shandong Province Natural Science Foundation (Grant No. ZR2010HZ004). The authors thank Professor Jian-Jun Wei (Department of Pathology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University) for advice on experimental design and critically reviewing the manuscript.